Type 2 diabetes medication rosiglitazone associated with increased cardiovascular risks and death, study finds
Monday, June 28, 2010 - 20:21
in Health & Medicine
A new study shows that among patients age 65 years and older, rosiglitazone (a medication for treating Type 2 diabetes) is associated with an increased risk of stroke, heart failure, and all-cause mortality (death) when compared with pioglitazone (another medication for diabetes).